Precision Neuroscience is a brain-computer interface (BCI) company developing high-resolution, minimally invasive neural implants to treat patients with neurological conditions. Founded in 2022 by members of the BrainGate research consortium, the company focuses on restoring independence for people with paralysis, stroke, and neurodegenerative diseases.
The company's founding team brings extensive experience from the BrainGate consortium, which has conducted pioneering research in neural interfaces for over two decades. This expertise provides a strong foundation for developing next-generation BCI technology that balances signal quality with surgical safety.
Precision Neuroscience's core technology is a thin-film, high-density micro-ECoG array that sits on the surface of the brain beneath the dura mater. This approach represents a significant advancement over traditional invasive BCI methods:
Key features include:
- High Spatial Resolution: Much higher than standard ECoG or EEG, enabling finer neural decoding
- Minimally Invasive: Does not require brain penetration, dramatically reducing surgical risk
- Broad Cortical Coverage: Can cover large brain areas with uniform signal quality
- Chronic Implantation: Designed for long-term use with minimal tissue response
- Thin-Film Construction: Ultra-flexible substrate conforms to brain surface anatomy
The pECoG array incorporates advanced engineering:
| Parameter |
Specification |
| Electrode Density |
>1000 electrodes/cm² |
| Spatial Resolution |
50-100 μm |
| Frequency Range |
0.5-500 Hz |
| Impedance |
<10 kΩ at 1 kHz |
| Biocompatibility |
FDA-approved materials |
| Thickness |
<10 μm |
Unlike fully invasive approaches like Neuralink or Blackrock Neurotech that penetrate brain tissue, Precision Neuroscience's pECoG approach offers unique advantages:
- Surface Placement: Sits on the brain surface, avoiding damage to neural tissue
- Higher Signal Quality: Provides signals with significantly higher spatial resolution than scalp EEG
- Middle Ground: Offers optimal balance between safety and signal quality
- Reduced Immune Response: Less tissue damage leads to more stable long-term signals
The primary application is enabling motor restoration for patients with:
- Spinal Cord Injury: Restoring voluntary movement through neural decoding
- Stroke: Supporting rehabilitation and potential motor recovery
- Amyotrophic Lateral Sclerosis (ALS): Maintaining communication and control
- Multiple Sclerosis: Preserving motor function in progressive disease
For neurodegenerative diseases, Precision Neuroscience's technology offers significant potential:
- Neural Monitoring: High-resolution recording for studying disease progression in Alzheimer's and Parkinson's
- Brain-Computer Interface Control: Enable external device control through decoded neural signals
- Rehabilitation Support: Motor rehabilitation through closed-loop feedback
- Biomarker Discovery: Detailed neural signatures for disease progression tracking
The high-resolution recording capabilities enable novel Alzheimer's research:
- Hippocampal Cortical Dynamics: Recording from surface electrodes over temporal regions
- Memory Circuit Mapping: Identifying functional changes in memory-related networks
- Treatment Response Monitoring: Objective neural markers for therapeutic efficacy
- Early Detection: High-resolution signals may reveal preclinical changes
For Parkinson's disease, the technology offers:
- Motor Cortex Recording: Understanding cortical involvement in parkinsonian syndromes
- Deep Brain Stimulation Integration: Potential for closed-loop DBS systems
- Levodopa Response Monitoring: Objective measures of medication effects
- Dyskinesia Detection: Early identification of treatment complications
Precision Neuroscience has achieved significant milestones:
- Successful Early Human Implantations: Proof-of-concept demonstrations
- Regulatory Clearance: Received FDA approval for clinical studies
- High-Quality Signal Recording: Demonstrated excellent neural signal quality in humans
- Safety Profile: No serious adverse events in initial trials
The company was founded by alumni of the BrainGate research consortium, which has a long history of neural interface research. This expertise provides:
- Proven Track Record: Decades of experience in neural decoding
- Clinical Trial Experience: Established protocols for BCI trials
- Academic Partnerships: Collaborations with leading research institutions
- Regulatory Knowledge: Understanding of FDA approval processes
¶ Competitive Landscape
Precision Neuroscience occupies a unique position in the BCI landscape:
| Company |
Approach |
Invasiveness |
Key Feature |
| Neuralink |
Penetrating |
High |
Highest bandwidth |
| Blackrock |
Penetrating |
High |
Longest clinical history |
| Synchron |
Endovascular |
Moderate |
Minimally invasive implantation |
| Precision Neuroscience |
Surface |
Moderate |
High resolution, minimal tissue damage |
- Safety Profile: Lower risk than penetrating electrodes
- Signal Quality: Superior to non-invasive approaches
- Scalability: Potential for broader patient populations
- Chronic Stability: Reduced glial scarring compared to penetrating arrays
Precision Neuroscience is pursuing several development paths:
- Expanded Clinical Trials: Larger studies across multiple indications
- Next-Generation Arrays: Higher electrode counts and improved materials
- Wireless Systems: Eliminating external hardware requirements
- Integrated Systems: Combining recording with stimulation capabilities